

# AKTIS ONCOLOGY INC.



## Company Overview

Aktis Oncology Inc. (“Aktis Oncology”) is a clinical-stage biotechnology company developing targeted radiopharmaceutical therapies for the treatment of solid tumors. The company utilizes a proprietary miniprotein radioconjugate platform designed to deliver radioactive isotopes directly to cancer cells, enabling highly targeted tumor destruction while minimizing exposure to surrounding healthy tissue.

**Operating segments** consist primarily of research and development activities focused on the discovery and clinical advancement of radiopharmaceutical oncology candidates. The company’s lead program targets Nectin-4 expressing tumors, including locally advanced or metastatic urothelial cancer, through the development of radioconjugate therapies designed for precision delivery of radioisotopes.

**Competitive positioning** is supported by its differentiated miniprotein platform technology, which is designed to enable improved tumor penetration and highly specific targeting of cancer biomarkers. Aktis Oncology is part of the emerging radiopharmaceutical oncology field, a rapidly growing segment of precision oncology.

**Strategic focus** centers on advancing clinical trials for its lead radiopharmaceutical programs, expanding its pipeline of targeted radioisotope therapies, securing strategic pharmaceutical partnerships, and progressing toward late-stage clinical development for commercialization.

**Headquarters:** New York, New York, United States

**Number of employees:** Approximately 76

## 1. Top 5 Competitors

- **RayzeBio Inc.** – Radiopharmaceutical oncology company developing targeted radioisotope therapies for solid tumors.
- **Fusion Pharmaceuticals Inc.** – Developer of targeted alpha-emitting radiopharmaceutical therapies.
- **Telix Pharmaceuticals Ltd.** – Radiopharmaceutical company focused on diagnostic and therapeutic oncology agents.
- **Novartis AG** – Global pharmaceutical company with radioligand therapies such as Lutathera and Pluvicto.
- **POINT Biopharma Global Inc.** – Clinical-stage radiopharmaceutical developer targeting oncology indications.

# AKTIS ONCOLOGY INC.



## 2. Largest Institutional Shareholders

(Estimated from latest available institutional filings; percentages rounded.)

Shareholder	% Ownership	Shares (Millions)
MPM BioImpact LLC	~19.5%	~10.3M
Eli Lilly and Company	~12.1%	~6.3M
Vida Ventures Advisors	~11.1%	~5.8M
Vida Ventures II LLC	~10.8%	~5.7M
EcoR1 Capital LLC	~10.3%	~5.4M
EcoR1 Capital Fund Qualified LP	~10.1%	~5.3M
MPM Bioventures 2018 LP	~7.9%	~4.2M
Blue Owl Credit Private Fund Advisors	~4.6%	~2.4M
Blue Owl Healthcare Opportunities IV LP	~4.5%	~2.3M
MPM Oncology Innovations Fund LP	~1.6%	~0.8M

**Top 10 Institutional Ownership:** ~92–95%

**Total Institutional Ownership:** ~94–95%

## 3. Management Team

- **Samuel Waksal** – Co-Founder & Executive Chairman
- **David M. Reese, M.D.** – Chief Executive Officer
- **Adam Crystal, M.D., PhD** – Chief Medical Officer

# AKTIS ONCOLOGY INC.



- **David M. Schenkein, M.D.** – Senior Scientific Advisor
- **Katherine S. Wilkins** – Chief Financial Officer

Management remains focused on advancing clinical radiopharmaceutical programs and building strategic industry collaborations.

## 4. Revenue

### Latest fiscal year:

- FY2025 revenue totaled approximately **\$5.6 million**, reflecting early-stage collaboration and research activity.

### Recent quarterly performance:

- The company reported continued net losses typical for clinical-stage biotechnology firms, with net income of approximately **\$(60.6) million** and negative EBITDA as research investments increased.

### Forward outlook:

- Aktis Oncology is expected to remain in a pre-commercial stage as clinical trials progress.
- Near-term value drivers are tied primarily to clinical trial milestones, regulatory progress, and potential strategic partnerships with large pharmaceutical companies.

### Key revenue drivers:

- Clinical advancement of radiopharmaceutical pipeline
- Potential licensing agreements or strategic partnerships
- Regulatory designations and approvals
- Expansion of targeted oncology indications
- Long-term commercialization of radiopharmaceutical therapies

## 5. Institutions with Buy Recommendations

- Bank of America Securities
- Cowen
- JPMorgan
- BMO Capital Markets

Sell-side analysts highlight the company's differentiated radiopharmaceutical platform and growing investor interest in targeted radioisotope oncology therapies.

## 6. Analyst Sentiment Summary

**Consensus rating:** Buy

**Target price range:**

- **Low:** ~\$30
- **Median:** ~\$32

# AKTIS ONCOLOGY INC.



- **High:** ~\$34

Analyst sentiment reflects optimism regarding the long-term potential of radiopharmaceutical oncology therapies and the company's ability to generate meaningful clinical data in early-stage trials.

## 7. Insider Buying and Selling (Last 24 Months)

- Insider activity has been modestly positive over the past year.
- Several directors and large shareholders have reported open-market purchases of shares.
- Notably, significant insider purchases exceeding \$40 million have been disclosed by directors and major stakeholders.
- Activity appears supportive of management confidence in the company's clinical pipeline development.